BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy
Phase 3
Terminated
- Conditions
- Blood Loss, SurgicalPostoperative Hemorrhage
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 57
- Registration Number
- NCT00306150
Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer
Phase 3
Terminated
- Conditions
- Blood Loss, Surgical
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 104
- Registration Number
- NCT00306137
Bleeding Pattern Study
Phase 3
Completed
- Conditions
- Oral Contraceptive
- Interventions
- Drug: Valette (Dienogest/EE30, BAY86-5038)
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1315
- Registration Number
- NCT00302666
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Terminated
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 926
- Registration Number
- NCT00300885
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00299390
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
Phase 3
Completed
- Conditions
- Peripheral Vascular Diseases
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 261
- Registration Number
- NCT00296855
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Phase 3
Completed
- Conditions
- Metrorrhagia
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 190
- Registration Number
- NCT00293059
- Locations
- 🇺🇸
Clinical Physiology Associates, Inc., Fort Myers, Florida, United States
🇺🇸South Carolina Clinical Research Center, Columbia, South Carolina, United States
🇺🇸Advanced Research Associates, Corpus Christi, Texas, United States
Menorrhagia Study in Women With Treatment-resistant Menorrhagia
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00288691
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast NeoplasmsBreast Cancer, Metastatic
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 82
- Registration Number
- NCT00288249
Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1326
- Registration Number
- NCT00280657
© Copyright 2025. All Rights Reserved by MedPath